New methods to improve brain stimulation for Parkinson's disease treatment.
Circuit-specific, chemogenetic neuromodulation in nonhuman primates.
This study is exploring new ways to improve brain treatments for Parkinson's disease by using special techniques to target specific brain areas, with the hope of making therapies safer and more effective for people living with the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nathan S. Kline Institute for Psych Res NIH-funded |
| Lab location | 1 site (Orangeburg, United States) |
| Project ID | NIH-10854940 on NIH RePORTER |
What this research studies
This research aims to develop innovative neuromodulation techniques using chemogenetics in nonhuman primates to enhance the effectiveness of brain stimulation therapies for Parkinson's disease. By utilizing Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), the study focuses on selectively targeting specific brain circuits involved in motor symptoms. The approach includes advanced methods for delivering these receptors into neurons and assessing their impact through imaging and behavioral evaluations. Ultimately, the goal is to translate these findings into safer and more effective treatments for patients with Parkinson's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease who may benefit from advanced neuromodulation therapies.
Not a fit: Patients with conditions other than Parkinson's disease or those who are not suitable candidates for neuromodulation therapies may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for Parkinson's disease, reducing the risks associated with current surgical options.
How similar studies have performed: Previous research has shown promise in using chemogenetic approaches for neuromodulation, indicating potential for success in this novel application.
Where this research is happening
Orangeburg, United States
- Nathan S. Kline Institute for Psych Res — Orangeburg, United States (Active)
Researchers
- Principal investigator: Schroeder, Charles E — Nathan S. Kline Institute for Psych Res
- Study coordinator: Schroeder, Charles E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.